Expert Ratings for Ocular Therapeutix
Over the past 3 months, 4 analysts have published their opinion on Ocular Therapeutix (NASDAQ:OCUL) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.
Ocular Therapeutix Q1 EPS $(0.22) Beats $(0.26) Estimate, Sales $13.19M Miss $14.20M Estimate
Ocular Therapeutix (NASDAQ:OCUL) reported quarterly losses of $(0.22) per share which beat the analyst consensus estimate of $(0.26) by 15.38 percent. This is a 8.33 percent increase over losses of $(0.24) per share from
Earnings Scheduled For May 9, 2022
Companies Reporting Before The Bell
• Atlantica Sustainable (NASDAQ:AY) is likely to report quarterly loss at $0.08 per share on revenue of $277.90 million.
12 Health Care Stocks Moving In Friday’s After-Market Session
Gainers
Ocular Therapeutix (NASDAQ:OCUL) shares moved upwards by 12.3% to $4.01 during Friday's after-market session. The company's market cap stands at $307.7 million.
The Week Ahead In Biotech (April 17-April 23): J&J, Abbott Earnings, Adcom Test For TG Therapeutics And More
Biotech stocks retreated in the week ending April 14, lock-stepping with the broader market. The news flow was light during the holiday-shortened week and ahead of the imminent first-quarter reporting season.
JMP Securities Maintains Market Outperform on Ocular Therapeutix, Lowers Price Target to $22
JMP Securities analyst Jonathan Wolleben maintains Ocular Therapeutix (NASDAQ:OCUL) with a Market Outperform and lowers the price target from $30 to $22.